ERBB2 and breast cancer: ICP-MS in vitro studies indicated HER2-mediated uptake of Rh-sar-PD-trastuzumab in HER2-expressing breast cancer cells, with LA-ICP-MS images showing intercellular heterogeneity in Rh-sar-PD-trastuzumab uptake.